Aiolfi A, Cavalli M, Sozzi A, Lombardo F, Lanzaro A, Panizzo V, Bonitta G, Mendogni P, Bruni P G, Campanelli G, Bona D
Department of Biomedical Science for Health, Division of General Surgery, University of Milan, Istitituto Clinico Sant'Ambrogio, Via Luigi Giuseppe Faravelli, 16, 20149, Milan, Italy.
Department of Surgery, University of Insubria, Istituto Clinico Sant'Ambrogio, Milan, Italy.
Hernia. 2022 Feb;26(1):279-286. doi: 10.1007/s10029-021-02528-z. Epub 2021 Oct 30.
Hernia recurrence after laparoscopic repair is a perplexing problem. In an effort to reduce anatomical and clinical recurrences, different type of meshes have been used to bolster the esophageal hiatus.
The aim of this study was to assess safety, medium-term efficacy, and quality of life improvement after laparoscopic repair of hiatal hernia reinforced with a biosynthetic absorbable mesh (Phasix-ST).
Observational single-center retrospective single-arm cohort study (November 2015-February 2021). We included all adult patients (> 18 years old) who underwent laparoscopic paraesophageal hernia repair with Phasix-ST mesh and Toupet fundoplication.
Sixty-eight patients were included. The median postoperative stay was 3.2 days (range 2-9) and the postoperative complication rate was 11.7%. The median follow-up time was 27 months (range 1-53). No mesh-related complications were detected. Hernia recurrence was diagnosed in six patients (8.8%). The recurrence-free probability at 34 months was 0.89 (95% CI 0.807-0.988) while at 60 months was 0.86 (95% CI 0.76-0.97). Hernia recurrences were mostly observed between 21 and 36 months after the operation. None of the patients required surgical revision and all were managed with PPI. Postoperative dysphagia requiring endoscopic balloon dilatation occurred in 2.9% of patients. Compared to baseline, both the GERD-HRQL (15.2 ± 6.2 vs. 3.2 ± 3.1; p = 0.026) and all SF-36 items were significantly improved (p < 0.001).
Laparoscopic crura augmentation with Phasix-ST mesh combined with a Toupet fundoplication is safe and seems effective in the medium-term follow-up. Phasix-ST crural reinforcement resulted in low hernia recurrence rate with a sustained symptoms and quality of life improvement.
腹腔镜修补术后疝复发是一个棘手的问题。为了减少解剖学和临床复发,已使用不同类型的补片来加强食管裂孔。
本研究的目的是评估使用生物合成可吸收补片(Phasix-ST)加强腹腔镜修补食管裂孔疝后的安全性、中期疗效和生活质量改善情况。
观察性单中心回顾性单臂队列研究(2015年11月至2021年2月)。我们纳入了所有接受腹腔镜经食管旁疝修补术并使用Phasix-ST补片和Toupet胃底折叠术的成年患者(>18岁)。
纳入68例患者。术后中位住院时间为3.2天(范围2-9天),术后并发症发生率为11.7%。中位随访时间为27个月(范围1-53个月)。未检测到与补片相关的并发症。6例患者(8.8%)被诊断为疝复发。34个月时无复发概率为0.89(95%CI 0.807-0.988),60个月时为0.86(95%CI 0.76-0.97)。疝复发大多在术后21至36个月观察到。所有患者均无需手术翻修,均采用质子泵抑制剂治疗。2.9%的患者出现需要内镜球囊扩张的术后吞咽困难。与基线相比,GERD-HRQL(15.2±6.2 vs. 3.2±3.1;p=0.026)和所有SF-36项目均有显著改善(p<0.001)。
使用Phasix-ST补片联合Toupet胃底折叠术进行腹腔镜食管裂孔增强术在中期随访中是安全的,且似乎有效。Phasix-ST食管裂孔加强术导致疝复发率低,症状持续缓解,生活质量得到改善。